As to other antidiabetic agents, glucagon receptor peptide‐1 (GLP‐1) receptor agonists and dipeptidyl peptidase‐4 inhibitors, which increase endogenous GLP‐1, apparently improve hyperglycemia by acting in pancreas to diminish glucagon secretion and improve glucose‐stimulated insulin secretion. The gene discussed is INS; the disease is Hyperglycemia.